Hexyon Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to need to reduce injection burden in infants, strong government immunization programs, proven safety of combination vaccines, high pediatric disease prevention focus, support from global health organizations.

The growth in the forecast period can be attributed to expansion of birth cohort immunization coverage, growth in emerging market vaccination programs, increased funding for pediatric healthcare, preference for cost effective combination vaccines, improved cold chain infrastructure. Major trends in the forecast period include growth of combination pediatric vaccines, simplification of childhood immunization schedules, rising demand for hexavalent vaccines, expansion of routine infant immunization programs, increased adoption in national vaccination policies.

The growing pediatric population is expected to drive the expansion of the Hexyon market in the future. The pediatric population refers to individuals typically ranging from birth to 18 years old, including infants, children, and adolescents. This increase in the pediatric population is largely attributed to improvements in healthcare, reduced child mortality rates, and higher birth rates in certain regions. Hexyon is crucial for the pediatric population as it provides comprehensive protection against multiple serious infectious diseases. By combining vaccines for diphtheria, tetanus, pertussis, hepatitis B, polio, and Hib into a single shot, it reduces the vaccination burden and enhances adherence. For example, in August 2025, The Office for National Statistics (ONS), a UK-based provider of official statistics, reported that the total fertility rate (TFR) continued to decline, from 1.42 to 1.41 children per woman between 2023 and 2024, despite a year-on-year increase in the absolute number of births in 2024. Consequently, the rise in the pediatric population is contributing to the growth of the Hexyon market.

The increasing investment in research and development (R&D) is expected to drive further growth in the Hexyon market. R&D investments are rising due to the growing demand for innovation, technological advancements, and the need to address complex global health challenges. These R&D efforts benefit Hexyon by improving its formulation, enhancing its efficacy, and expanding its indications, ensuring it remains competitive in the evolving healthcare landscape. For example, in April 2025, The Office for National Statistics (ONS) reported that the UK government’s net R&D spending rose by 8.2% year-on-year, from $20 billion (£16.1 billion) in 2022 to about $21.6 billion (£17.4 billion) in 2023. As a result, the rising investment in R&D is fueling the growth of the Hexyon market.

A key trend in the Hexyon market is the focus on facility expansion to gain a competitive advantage. Facility expansion involves enhancing a company’s physical space or infrastructure to support growth, optimize operations, and improve services. For example, in November 2024, Sanofi S.A., a France-based pharmaceutical company, opened a $596 million modular manufacturing facility at Singapore's Tuas Biomedical Park. This state-of-the-art facility is designed to produce various vaccines and biopharmaceuticals simultaneously, utilizing advanced technologies and environmentally friendly practices. This expansion increases Sanofi's capacity to meet future health challenges and accelerate the delivery of essential treatments.

Major companies operating in the hexyon market are Sanofi S.A.

Europe was the largest region in the hexyon market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hexyon market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hexyon market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the hexyon market by raising costs related to vaccine production inputs, packaging materials, and international logistics. Public health programs and pediatric hospitals in import dependent regions face higher procurement costs. These pressures can influence vaccine rollout timelines and budgeting decisions. At the same time, tariffs are encouraging regional vaccine manufacturing investments. This is strengthening local supply capabilities and long term immunization security.

The hexyon market research report is one of a series of new reports that provides hexyon market statistics, including hexyon industry global market size, regional shares, competitors with a hexyon market share, detailed hexyon market segments, market trends and opportunities, and any further data you may need to thrive in the hexyon industry. This hexyon market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hexyon is a hexavalent vaccine designed to protect against six diseases: diphtheria, tetanus, pertussis, polio, hepatitis B, and Haemophilus influenzae type b. It is typically administered to infants and young children to provide immunity against these conditions. The vaccine is given as part of a routine immunization schedule and is valued for its convenience in combining multiple vaccines into a single dose.

The main types of Hexyon products include hexavalent vaccines, as well as monovalent and combination vaccines. Hexavalent vaccines are immunizations that protect against six different diseases with just one shot. It is used for pediatric immunization and catch-up vaccination, and is distributed through hospitals, clinics, public health programs, and pharmacies.

The hexyon market consists of sales of dupilumab, insulin glargine, agalsidase beta, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.